StoneX Group Inc. Buys 2,814 Shares of Eli Lilly and Company $LLY

StoneX Group Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 34.3% in the second quarter, HoldingsChannel reports. The firm owned 11,028 shares of the company’s stock after purchasing an additional 2,814 shares during the quarter. StoneX Group Inc.’s holdings in Eli Lilly and Company were worth $8,596,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Lazard Freres Gestion S.A.S. boosted its stake in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after acquiring an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK lifted its holdings in shares of Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $54,000. Finally, Duquesne Family Office LLC grew its stake in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.5%

Eli Lilly and Company stock opened at $1,009.26 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The stock has a market capitalization of $954.13 billion, a PE ratio of 49.38, a price-to-earnings-growth ratio of 1.13 and a beta of 0.37. The business’s fifty day moving average is $918.84 and its 200 day moving average is $809.30.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on LLY shares. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research report on Monday, November 10th. HSBC raised their price target on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. CICC Research increased their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Finally, Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,087.32.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.